Introduction
============

With the incidence of ischemic encephalopathy gradually increased, people have payed increased attention to the prevention and treatment of cerebral ischemia-reperfusion injury ([@b1-etm-0-0-5274],[@b2-etm-0-0-5274]). Cerebral infarction is a common cause of ischemic encephalopathy, thrombolytic therapy after cerebral infarction in time can save the lives of patients, but also may cause ischemia-reperfusion injury. Therefore, if the mechanism of ischemia-reperfusion injury is clear, it is of great significance for timely target treatment for ischemia-reperfusion injury. In recent years, there were more studies on ischemia-reperfusion injury, but there is still not a unified opinion on the prevention and treatment of ischemia-reperfusion injury. Studies showed that the expression of telomerase was increased in the brain tissues of patients with ischemia-reperfusion injury ([@b2-etm-0-0-5274],[@b3-etm-0-0-5274]), while some researchers found that telomerase was overexpressed after the injury of brain tissue, considering the protective effect of telomerase on ischemia-reperfusion injury in order to reduce the tissue damage ([@b4-etm-0-0-5274]). Human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) can secrete a variety of cytokines and neurotrophic factors and promote nerve regeneration, but the conventional route of administration can not fully play the role of hUCB-MSCs. So some scholars proposed nasal administration of hUCB-MSCs to improve neurological function in rats with ischemia-reperfusion injury ([@b5-etm-0-0-5274]). At present, the study of hUCB-MSCs on nerve injury in rats with ischemia-reperfusion injury is scarce. So the aim of our study was to investigate the effects of hUCB-MSCs on rats with ischemia-reperfusion injury, in order to explore the mechanism of the prevention and treatment of ischemia-reperfusion injury.

Materials and methods
=====================

### Animals

Experiments were performed using 100 healthy adult Wistar rats weighing 180--220 g, provided by College Animal Center, Harbin Medical University. Rats were kept in the animal house under constant temperature (18--25°C) and humidity (60 to 70%) on natural light with C060 sterilized commercial feed and free water intake, with 12 h before fasting. The study was approved by the Ethics Committee of Harbin Medical University.

### Modeling method

All rats were randomly divided into control group and observation group and treated with 10% chloral hydrate (3.5 ml/kg) at RT. After anesthesia, the middle cerebral artery ischemia-reperfusion model was established by the suture method, and the specific modeling method was according to the method given by Chopp and Li ([@b6-etm-0-0-5274]). Then the rats in the observation group were treated with hUCB-MSCs (10 ml/kg) by nasal administration for 14 days, with the saline in the control group. The neurological deficit score and foot fault test were evaluated at 1, 7 and 14 days after treatment, and the rats were sacrificed at 14 days to detect the expression of telomerase reverse transcriptase (TERT) in brain tissue.

The source of hUCB-MSCs: 30 ml human umbilical cord blood was taken under sterile conditions with heparin anticoagulant, then transferred into a 15 ml centrifuge tube and centrifuged at 2,800 × g for 20 min. The upper plasma was removed, collecting the white blood cells in interface layer, and stored at 4°C. The expression of TERT was detected by western blot analysis. The above operations are carried out by the researchers in our laboratory according to the instructions, and the reagents and kits were purchased from LanPai Biotechnology Co., Ltd. (Shanghai, China).

### Observation and evaluation of indicators

### The criteria for mNSS ([@b7-etm-0-0-5274])

The four aspects as sensory, motor, reflex and muscle tensionin of rats were scored with the total score of 18. The higher the score, the more serious the nerve damage.

### Foot fault test

The foot fault test was used to evaluate the disorder of rat forelimb, placing the rats on the Hanging mesh grid (2.5×2.5 cm), then recording the total number of bilateral forelimb movement and the number of left forelimb foot errors. The percent of the number of left forelimb foot errors to the total number of bilateral forelimb movement as the statistical results.

### Statistical analysis

The statistical analysis was performed with SPSS 21.0 (IBM Corp., Armonk, NY, USA) and the obtained data are in normal distribution. Measurement data were expressed as mean ± SD and the t-test was performed. Counting data were calculated by Chi-square test. A P-value \<0.05 was considered as a significant difference.

Results
=======

### Comparison of neurological deficit score between the two groups

There was no significant difference in the scores of mNSS between the two groups before the model establishment (P\>0.05), but after the model established there was significant difference in two groups respectively (P\<0.05). At 1 day after the operation, the mNSS score of two groups was peaked, which was decreased in the groups with the progress of treatment. The degree of decline in the observation group was significantly greater than that in the control group (P\<0.05; [Table I](#tI-etm-0-0-5274){ref-type="table"}).

### Comparison of foot fault number between the groups

There was no significant difference in the foot fault number between the two groups before ischemia-reperfusion model establishment (P\>0.05), but after the model established the foot fault frequency was significantly increased in each group. At 1 day after operation, the number of foot errors peaked, but it was decreased in the groups with the progress of treatment. The number of foot errors was decreased significantly in the observation group compared to that in the control group (P\<0.05; [Table II](#tII-etm-0-0-5274){ref-type="table"}).

### The gray value of TERT content in brain tissue in the two groups

The gray value of TERT content in the observation group was 0.983±0.056 LOD, which was significantly higher than that in the control group with the gray value of 0.458±0.052 LOD (P\<0.05; [Table III](#tIII-etm-0-0-5274){ref-type="table"}).

### Comparison of groups of rats with brain tissue immunohistochemical reaction

The H&E staining showed the nucleus or cytoplasm in the brain tissue of rats was brown or yellow brown in the observation group, which showed positive reaction ([Fig. 1A](#f1-etm-0-0-5274){ref-type="fig"}). The cytoplasm and the nucleus were stained yellow in the control group, suggested the neurons were shrunken ([Fig. 1B](#f1-etm-0-0-5274){ref-type="fig"}).

### TERT protein expression in two groups

As [Fig. 2](#f2-etm-0-0-5274){ref-type="fig"} shows, the expression of TERT protein in brain tissue of rats in observation group was significantly decreased compared to that in the control group.

Discussion
==========

Ischemia and hypoxia is an important factor for tissue necrosis. For the brain tissue, short-term ischemia and hypoxia can cause irreversible tissue damage ([@b8-etm-0-0-5274]). In recent years, with the deep study of ischemic diseases, increased number of studies found that ischemia is not the only factor for the tissue damage ([@b9-etm-0-0-5274]). Free radical release caused by ischemia-reperfusion plays an important role in the tissue injury induced by ischemia and hypoxia, which is known as ischemia-reperfusion injury. Telomerase refers to an enzyme that is responsible for telomere elongation in cells and is a basic nucleoprotein reverse transcriptase that binds telomere DNA to the eukaryotic chromosome ends. The primary role of telomerase is to maintain telomere integrity and prevents its loss in cell division ([@b10-etm-0-0-5274]). The activity of telomerase is inhibited in normal cells, but it can be significantly activated in tumor cells. TERT, as a catalytic subunit of telomerase, not only activates telomerase activity, but also protects mitochondria and has an anti-apoptotic effect. Studies showed that TERT can effectively improve neuronal apoptosis and neurological function in patients with ischemia-reperfusion injury ([@b11-etm-0-0-5274]). Stem cell therapy is a more popular treatment in recent years, which have a good therapeutic effect for some diseases. Some scholars have found that hUCB-MSCs contains a variety of cytokines and nerve growth factors, which can effectively improve neuronal damage, but these growth factors can not pass through the blood-brain barrier ([@b12-etm-0-0-5274]). Nasal administration not only allows drugs to enter the brain tissue, but also reduces the loss of stem cells.

In this study, there were no significant differences in the scores of mNSS between the two groups before the model establishment (P\>0.05), but there was significant differences in two groups after the operation (P\<0.05). At 1 day after the operation, the mNSS score of two groups peaked, which was decreased in the groups with the progress of treatment. The degree of decline in the observation group was significantly greater than that in the control group (P\<0.05). Similarly, there were no significant differences in the number of preoperative footsteps between the two groups before the model establishment (P\>0.05), but there was significant differences in two groups after the operation (P\<0.05). At 1 day after the operation, the number of preoperative footsteps was peaked, which was reduced in the groups with the progress of treatment. The degree of reduction in the observation group was significantly greater than that in the control group (P\<0.05). The results in our study showed that hUCB-MSCs could effectively reduce the neurological injury of rats with ischemia-reperfusion injury, which was consistent with the decrease of neuronal apoptosis in brain tissue. Zhao *et al* also found that after administration of hUCB-MSCs, neuronal dysfunction in rats with ischemia-reperfusion injury was improved, which was possibly related to the effects of TERT on promoting astrocyte proliferation and activation, increasing hypoxia ischemic rat brain astrocytes proliferation and promoting neuronal survival ([@b13-etm-0-0-5274]). With the gray value of the TERT protein as 0.458±0.052 LOD in the control group, which was significantly lower than that in the observation group with 0.983±0.056 LOD, which suggested that hUCB-MSCs could effectively promote the expression of TERT in brain tissue of rats with ischemia-reperfusion. Chen *et al* also found that hUCB-MSCs significantly increased the expression of TERT protein in rat brain by nasal administration, possibly related to the effect of hUCB-MSCs on promoting the expression of TERT in brain tissue induced by cytokines and neurotrophic factors ([@b14-etm-0-0-5274]).

In conclusion, hUCB-MSCs can effectively improve the neurological function of cerebral ischemia-reperfusion injury in rats and improve the expression of TERT in brain tissue, which may help to reduce cerebral ischemia-reperfusion injury.
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![H&E staining of the rat brain tissue immunohistochemical reaction. (A) The nucleus or cytoplasm was brown or yellow brown in the observation group, which showed positive reaction. (B) The cytoplasm and the nucleus were stained yellow in the control group, suggested the neurons were shrunken.](etm-14-06-5843-g00){#f1-etm-0-0-5274}

![The expression of TERT protein in brain tissue of rats. A, the control group; B, the observation group; TERT, telomerase reverse transcriptase.](etm-14-06-5843-g01){#f2-etm-0-0-5274}

###### 

Neurological deficit score in two groups (mean ± SD).

                           mNSS score                                                                                                                                                                     
  ------------------- ---- ------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  Control group       50   0.56±0.12    11.51±0.56^[a](#tfn1-etm-0-0-5274){ref-type="table-fn"}^   8.52±0.84^[a](#tfn1-etm-0-0-5274){ref-type="table-fn"}^                                                6.85±1.25^[a](#tfn1-etm-0-0-5274){ref-type="table-fn"}^
  Observation group   50   0.58±0.14    10.54±0.58^[a](#tfn1-etm-0-0-5274){ref-type="table-fn"}^   4.59±0.68^[a](#tfn1-etm-0-0-5274){ref-type="table-fn"},^[b](#tfn2-etm-0-0-5274){ref-type="table-fn"}   3.25±0.52^[a](#tfn1-etm-0-0-5274){ref-type="table-fn"},^[b](#tfn2-etm-0-0-5274){ref-type="table-fn"}
  Group                                 F=12.32, P=0.002                                                                                                                                                  
  Time                                  F=8.12, P=0.026                                                                                                                                                   
  Time group                            F=9.15, P=0.012                                                                                                                                                   

P\<0.05 compared with the preoperative score

P\<0.05 compared with control group.

###### 

The number of foot errors in the two groups (mean ± SD).

                           Wrong steps                                                                                                                                                                      
  ------------------- ---- ------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Control group       50   0.44±0.15     29.5±3.82^[a](#tfn3-etm-0-0-5274){ref-type="table-fn"}^    23.65±3.43^[a](#tfn3-etm-0-0-5274){ref-type="table-fn"}^                                                16.98±2.68^[a](#tfn3-etm-0-0-5274){ref-type="table-fn"}^
  Observation group   50   0.42±0.12     28.32±3.46^[a](#tfn3-etm-0-0-5274){ref-type="table-fn"}^   20.32±3.24^[a](#tfn3-etm-0-0-5274){ref-type="table-fn"},^[b](#tfn4-etm-0-0-5274){ref-type="table-fn"}   6.52±1.87^[a](#tfn3-etm-0-0-5274){ref-type="table-fn"},^[b](#tfn4-etm-0-0-5274){ref-type="table-fn"}
  Group                                  F=10.45, P=0.002                                                                                                                                                   
  Time                                   F=7.43, P=0.034                                                                                                                                                    
  Time group                             F=8.65, P=0.027                                                                                                                                                    

P\<0.05 compared with preoperative foot errors

P\<0.05 compared with control group.

###### 

The gray value of TERT content in brain tissue of the two groups (mean ± SD).

  Group               n    TERT (WB, LOD)
  ------------------- ---- ----------------
  Control group       50   0.458±0.052
  Observation group   50   0.983±0.056
  T value                  8.62
  P-value                  \<0.05

TERT, telomerase reverse transcriptase.
